Wells Fargo lowered the firm’s price target on Integra LifeSciences (IART) to $13 from $25 and keeps an Equal Weight rating on the shares. The firm says that following Q1 earnings, it is hard to make the case for multiple expansion, and Wells would like to see consistent management execution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences Reports Q1 2025 Financial Results
- Integra LifeSciences Earnings Call: Mixed Results Amid Challenges
- Morning Movers: Skechers surges following take-private deal
- Integra LifeSciences lowers adj 2025 EPS view to $2.19-$2.29 from $2.41-$2.51
- Integra LifeSciences reports Q1 adjusted EPS 41c, consensus 43C